Prosecution Insights
Last updated: November 20, 2026
Application No. 18/701,358

RNA-GUIDED TRANS-SPLICING OF RNA

Non-Final OA §102§103
Filed
Apr 15, 2024
Priority
Oct 15, 2021 — provisional 63/256,337 +1 more
Examiner
STAVROU, CONSTANTINA E
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Massachusetts Institute of Technology
OA Round
1 (Non-Final)
42%
Grant Probability
Moderate
1-2
OA Rounds
1y 3m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allowance Rate
39 granted / 93 resolved
-18.1% vs TC avg
Strong +36% interview lift
Without
With
+36.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
58 currently pending
Career history
175
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
43.1%
+3.1% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
30.1%
-9.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 93 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group I, claims 1, 4, 10, 12-13, 17-23, and 35-42 in the reply filed on 08/07/2026 is acknowledged. Because Applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 24-25, 28-31, and 33-34 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected group, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/07/2026. Status of the Claims Claims 1, 4, 10, 12-13, 17-25, 28-31, and 33-42 are currently pending. Claims 24-25, 28-31, and 33-34 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Invention, there being no allowable generic or linking claim. Claims 2-3, 5-9, 11, 14-16, 26-27, and 32 are cancelled. Claims 1, 4, 10, 12-13, 17-23, and 35-42 have been considered on the merits. Information Disclosure Statement An IDS was received on 04/15/2024 and 08/07/2026. All references have been considered; however, due to the voluminous number of references in the IDS they have been only briefly considered. It is noted that the cloaking of a relevant reference by inclusion in a long list of citations may not comply with the Applicant' s duty of disclosure. Penn Yan Boats, Inc. v. Sea Lark Boats, Inc., 359 F. Supp. 948 (S.D. Fla. 1972). Therefore, the applicant is encouraged to present a concise statement as to the relevance of any particular documents known to be material for patentability as defined by 37 C.F.R. § 1.56. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 4, 10, 12-13, 17, 19-23, and 35-42 are rejected under 35 U.S.C. 102(a)(1)/102(a)(2) as being anticipated by Gao et al (WO2021076656A1). Regarding claim 1, Gao teaches an engineered composition comprising a catalytically inactive, RNA-binding, Cas polypeptide (dCas) ([0011]). Gao teaches a trans-splicing donor construct comprising a guide sequence, an intron comprising a splice acceptor, a donor RNA, (See Claim 1 of Gao) and a polyA tail ([0085]/[0145]). Gao teaches that the guide is capable of forming a complex with the dCas and directing sequence specific binding of the complex to a mRNA through teaching that the “dead” Cas retains functionality but lacs nuclease activity ([0052]). Regarding claim 4, Gao teaches that the composition contains a guide which specifically binds to an intron-exon boundary that is 5’ relative to a mutant exon of a gene of interest and the donor RNA comprises an exon od the target precursor mRNA and a heterologous sequence to be spliced into the target mRNA ([0004]/[0025]/[0075]). Regarding claim 10, Gao teaches that the replacement exon contains one more mutations relative to the target exon and/or corrects one or more mutations present in the target exon ([0108]). Regarding claim 12, Gao teaches that the trans-splicing donor construct is fused to the 3’ end of the guide sequence (See Fig. 5, and [0034]). Regarding claim 13, Gao teaches that the dCas polypeptide is a Cas13d ([0017]/claim 23). Regarding claim 17, Gao teaches fusing the pre-trans-splicing molecule with the gRNA of Cas13 to improve the specificity and efficiency of the spliceosome-mediated RNA trans-splicing process ([0145]). Regarding claim 19, Gao teaches a polynucleotide encoding one or more of the components of the composition of claim 1 ([0058]). Regarding claim 20, Gao teaches a vector system comprising one or more vectors encoding one or more components of the composition of claim 1 ([0058]). Regarding claim 21, Gao teaches a cell or population of cells comprising the composition of claim 1 ([0014]). Regarding claim 22, Gao teaches that the compositions of their invention may be combined with a pharmaceutically acceptable carrier ([0125]). Regarding claim 23, Gao teaches the composition of claim 1 ([0011]/[0085]/[0145]/[0052]). Regarding claim 35, Gao teaches a cell or population of cells comprising the polynucleotide of claim 19 ([0058] and [0014]). Regarding claim 36, Gao teaches that the compositions of their invention may be combined with a pharmaceutically acceptable carrier to form a pharmaceutically acceptable formulation ([0125]). Regarding claim 37, Gao teaches the polynucleotide of claim 19 ([0058]). Regarding claim 38, Gao teaches a cell population comprising the vector system of claim 20 ([0058]/[0092]). Regarding claim 39, Gao teaches that the compositions of their invention may be combined with a pharmaceutically acceptable carrier to form a pharmaceutically acceptable formulation ([0125]). Regarding claim 40, Gao teaches the vector system of claim 20 ([0058]. Regarding claim 41, Gao teaches the cell or population of cells as in claim 21 ([0014]). Regarding claim 42, Gao teaches the pharmaceutical formulation of claim 22 ([0125]). Thus, Gao anticipates the claims. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 18 is rejected under 35 U.S.C. 103 as being unpatentable over Gao et al (WO2021076656A1), as applied to claims 1, 4, 10, 12-13, 17, 19-23, and 35-42 above, and in view of Cheng et al (WO2020069331A1). With regards to claim 18, the limitations of the independent claim are taught above. Gao does not explicitly teach that the one or more domains fused to or otherwise capable of associating with the Cas polypeptide to improve recruitment of spliceosome or efficiency of target search and hybridization by the guide sequence are RBFOX1 and/or RBM38 as required by claim 18. However, Cheng teaches a similar embodiment to that of Gao in that Cheng provides compositions which are able to induce exon inclusion/exclusion events by employing a catalytically inactive programmable nuclease such as dCas (abstract). Regarding claim 18, Cheng teaches that an artificial RNA-guided splicing factor comprising an RNA splicing factor which can be RBFOX1 and RBM38 linked to a dCas (pg. 2, para 1-2). Cheng states that the versatile artificial RNA-guided splicing factor is used to induce exon inclusion/exclusion events at precise locations within a target gene or another genomic locus of interest (pg. 1, para 3). One of ordinary skill in the art would find it obvious at the effective filling date of the instant invention to combine the dCas system containing a domain capable of associating to the dCas polypeptide improving recruitment of spliceosome and efficiency of target search and hybridization taught by Gao with the dCas system containing splicing factors RBFOX1 and/or RBM38 taught by Cheng to arrive at the instant invention. One of ordinary skill in the art would be motivated to make this combination because Cheng states that the versatile artificial RNA-guided splicing factor is used to induce exon inclusion/exclusion events at precise locations within a target gene or another genomic locus of interest (pg. 1, para 3). One of ordinary skill in the art would have a reasonable expectation of success when combining Gao with Cheng because both provide dCas systems for the editing of target exons and teach the necessary information to do so. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the effective time of filing of the invention, especially in the absence of evidence to the contrary. Conclusion No claims are allowed. Examiner Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to CONSTANTINA E STAVROU whose telephone number is (571)272-9899. The examiner can normally be reached M-F 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CONSTANTINA E. STAVROU Examiner Art Unit 1632 /TITILAYO MOLOYE/Primary Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

Apr 15, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766167
COMPOSITIONS AND METHODS OF TREATMENT OF VISION LOSS THROUGH GENERATION OF ROD PHOTORECEPTORS FROM MÜLLER GLIAL CELLS
6y 0m to grant Granted Oct 20, 2026
Patent 12760083
CHIMERIC RECEPTOR THERAPY
4y 9m to grant Granted Oct 13, 2026
Patent 12747423
CELL CULTURE MEDIUM FOR CULTURING EXTRACELLULAR VESICLES AT HIGH CONCENTRATION AND METHOD FOR PREPARING CONDITIONED MEDIUM CONTAINING HIGH CONCENTRATION OF EXTRACELLULAR VESICLES USING CELL CULTURE MEDIUM
5y 8m to grant Granted Sep 29, 2026
Patent 12716058
METHODS FOR DIRECTED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO HLA HOMOZYGOUS IMMUNE CELLS
7y 4m to grant Granted Aug 25, 2026
Patent 12678463
ACTIVATED MESENCHYMAL STEM CELLS FOR TREATING LIMB ISCHEMIA
4y 4m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
42%
Grant Probability
78%
With Interview (+36.1%)
3y 11m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 93 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month